← Back to Patent Explorer
US5262424A Expired / Lapsed US ⏱️ 0.0 years remaining

Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith

Assignee: Wyeth LLC
•
Filing: 1992-11-17
•
Granted: 1993-11-16
•
Expires: 2012-11-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A compound of the structure ##STR1## wherein R 1 and R 2 are each, independently, hydrogen or --CONHSO 2 --Ar; and Ar is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted; with the proviso that R 1 and R 2 are not both hydrogen; or a pharmaceutically acceptable salt thereof which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections.

Inventors

  • 👤 Wenling Kao

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 12:26
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/12; C07D498/18

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 181 words
A method of treating transplantation rejection, host vs. draft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering an immunosuppressive effective amount of a compound having the structure ##STR4## wherein R 1 and R 2 are each, independently, hydrogen or --CONHSO 2 --Ar; and Ar is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted with a group selected from alkyl of 1-6 carbon atoms, aryllalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, --SO 3 H, --PO 3 H, and --CO 2 H; with the proviso that R 1 and R 2 are not both hydrogen; or a pharmaceutically acceptable salt thereof when the Ar group contains a basic nitrogen or when the Ar group is substituted by dialklyamino of 1-6 carbon atoms per alkyl group, --SO 3 H, --PO 3 H, or --CO 2 H.
Claim 2
Independent Claim 181 words
A method of treating transplantation rejection, host vs. draft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering an immunosuppressive effective amount of a compound having the structure ##STR4## wherein R 1 and R 2 are each, independently, hydrogen or --CONHSO 2 --Ar; and Ar is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted with a group selected from alkyl of 1-6 carbon atoms, aryllalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, --SO 3 H, --PO 3 H, and --CO 2 H; with the proviso that R 1 and R 2 are not both hydrogen; or a pharmaceutically acceptable salt thereof when the Ar group contains a basic nitrogen or when the Ar group is substituted by dialklyamino of 1-6 carbon atoms per alkyl group, --SO 3 H, --PO 3 H, or --CO 2 H.
Claim 3
Dependent Claim 173 words
A pharmaceutical composition for use as an immunosuppressive agent comprising an immunosuppressive amount of a compound of the structure ##STR5## wherein R 1 and R 2 are each, independently, hydrogen or --CONHSO 2 --Ar; and Ar is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted with a group selected from alkyl of 1-6 carbon atoms, aryllalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, --SO 3 H, --PO 3 H, and --CO 2 H; with the proviso that R 1 and R 2 are not both hydrogen; or a pharmaceutically acceptable salt thereof when the Ar group contains a basic nitrogen or when the Ar group is substituted by dialklyamino of 1-6 carbon atoms per alkyl group, --SO 3 H, --PO 3 H, or --CO 2 H and a pharmaceutical carrier.
Claim 4
Dependent Claim 173 words
A pharmaceutical composition for use as an immunosuppressive agent comprising an immunosuppressive amount of a compound of the structure ##STR5## wherein R 1 and R 2 are each, independently, hydrogen or --CONHSO 2 --Ar; and Ar is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted with a group selected from alkyl of 1-6 carbon atoms, aryllalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, --SO 3 H, --PO 3 H, and --CO 2 H; with the proviso that R 1 and R 2 are not both hydrogen; or a pharmaceutically acceptable salt thereof when the Ar group contains a basic nitrogen or when the Ar group is substituted by dialklyamino of 1-6 carbon atoms per alkyl group, --SO 3 H, --PO 3 H, or --CO 2 H and a pharmaceutical carrier.

References Cited (Backward Citations)

US3929992A Cited
US3993749A Cited
US4885171A Cited
US4316885A Cited
US4401653A Cited
US4650803A Cited
US5100899A Cited
US5080899A Cited
US5078999A Cited
US5100883A Cited
US5118678A Cited
US5091389A Cited
US5169851A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-11-15 1997-05-17 1997-11-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-11-15 2001-05-17 2001-11-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-11-15 2005-05-17 2005-11-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag